Atlas Trials

Stage IV Major Salivary Gland Cancer AJCC v8

5 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Stage IV Major Salivary Gland Cancer AJCC v8

RecordFirmDate
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (NCT05408845)NRG Oncology2023-03-03
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091)National Cancer Institute (NCI)2022-07-06
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)National Cancer Institute (NCI)2021-08-09
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer (NCT04895735)Mayo Clinic2021-07-23
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers (NCT03749460)University of Washington2019-01-15

Track Stage IV Major Salivary Gland Cancer AJCC v8 automatically

Every clearance here is in the API, with alerts when new ones post.